How To Make International Pull Incentives Work In Fight Against AMR

Global action on delivering pull incentives for the development of new antibiotics is urgently required, according to a new report that sets out how countries could join together to make incentives attractive enough for companies to invest in this space.

Action required - word abstract in vintage letterpress wood type
Action is urgently needed to address antimicrobial resistance • Source: Shutterstock

Countries around the world could come together to fund a global pull incentive, worth around $4.2bn, to encourage the development of new antibiotics, according to a new industry-sponsored report that says the need for international action on antimicrobial resistance (AMR) is increasingly urgent.

The report, Incentivising new antibiotics, from the UK Office of Health Economics, describes a “globally aligned, value-based, fully delinked pull...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from International

More from Geography

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.